FGH10019 is a novel sterol regulatory element-binding protein ( SREBP ) inhibitor with IC 50 of 1 μM.
In Vitro
Treatment of the CHO-K1 cells with analog FGH10019 decreases the percentage of the mature form of SREBP-2 (68 kDa) at lower concentrations than treatment with fatostatin. Densitometric analysis of the gels indicates that the IC 50 of analog FGH10019 is approximately 1 μM, which is 5-10 times lower than the IC 50 of fatostatin (appr 10 μM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
FGH10019-treated chow is fed at a dose rate calculated to provide about 0.7 mg analog FGH10019 per day, at about 23 mg/kg body weight, to 5-wk-old male ob/ob mice weighing an average of appr 30 g. After 8 wk on the analog 24-treated chow, the mice gain 8-9 % less weight than control mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:IC50: 1 μM (SREBP)
Associated Targets(Human)
SREBF2TchemSterol regulatory element-binding protein 2 (2 Activities)
